Please assess the completion status of the following clinical trial:

Trial Title: IDO Peptid Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histological or cytological verified non small cell lung cancer 2. Metastatic or locally advanced incurable stage III-IV NSCLC 3. Patients need to be off chemotherapy treatment 4. Evaluable disease according to RECIST V. 1,1 criteria 5. Patients must be HLA-A2 positive 6. Patients \> 18 years old 7. Performance status 0-1 8. Life expectancy of \> 3 months 9. Acceptable bone marrow function, defined as~a. White blood cell count \> 2,5 \* 109 /l b. Neutrophil count\> 1,5 \* 109 /l c. Platelet count \> 75 \* 109/l 10. Creatinin measured \< 2,5 \* upper limit value 11. Acceptable liver function, defined as~1. ASAT \< 100 U/L~2. Bilirubin \< 30 U/L 12. Women with child-bearing potential must have controlled s-hcg before inclusion 13. Patients must provide written informed concent before inclusion 13. Termination of chemotherapy treatment \> 28 days before inclusion~   14. Termination of radiotherapy treatment \> 28 days before inclusion~   15. Inclusion at least \> 4 weeks after complicated gastric surgery~   -~   Exclusion Criteria:~  1. Other malignancies except from non-melanoma skin cancer in the previous 5 years until study inclusion~  2. Brain metastasis are allowed after radical excision, and if the patient at least 1 month afterwards is not in clinical or radiographic progression~  3. Patients with active gastric ulcer disease; patients taking antacid treatment can be included.~  4. Severe medical condition, severe asthma, severe COLD, severe arteriosclerosis or diabetic disease~  5. Acute or chronic infection (ie. HIV, hepatitis, tuberculosis)~  6. Severe allergic reaction or previous anaphylactic shock~  7. Autoimmune diseases (ie. autoimmune neutropenia/thrombopenia, hæmolytic anaemia, systemic lupus erythematosis, Sjøgrens disease, sclerodermia, Goodpastures syndrome, Addisons disease, active Graves disease)~  8. Pregnant or lactating women~  9. Psychiatric disease, which can influence compliance~  10. Known hypersensitivity towards the adjuvance Montanide, the Aldara creme, or adhesive tape.~  11. Treatment with immunosuppressive therapy (ie. dexamethasone, methotrexate)~  12. Treatment with other experimental therapy~  13. Treatment with other anti-cancer therapy, except from treatment of osteoporosis~  14. No systemic chemotherapy, immunotherapy or radiation therapy (except locally) are allowed until 28 days before inclusion.~       -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indeolamine 2,3 deoxygenase (Type: EXPERIMENTAL): To inhibit immune suppression and tolerance, by blocking the IDO enzyme with vaccination against IDO.

Based on this trial design, predict the completion outcome and termination type (if applicable).